Longtime Bay Area cancer biotech snagged by Amgen in $1.9B deal

The Peninsula biotech shed more than half its jobs in recent years but stayed focused on its gastric cancer drug bemarituzumab, which is ready for Phase III clinical trials and could be used to attack a number of other types of cancer.

Source: bizjournals.com Health Care:Pharmaceuticals headlines - March 5, 2021 Category: Pharmaceuticals Authors: Ron Leuty Source Type: news